BIIB•benzinga•
Reported Earlier, Eisai And Biogen Announced FDA Acceptance Of LEQEMBI BLA For Weekly Subcutaneous Dosing To Treat Early Alzheimer's Disease
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 14, 2025 by benzinga